Who Tests the Vials?

Last updated: October 18, 2026

A gray market runs on trust documents — and in this market, the core trust document, the certificate of analysis, has been forged in a federal case (Paradigm Peptides). That failure created an independent testing layer: services and watchdogs that re-test products, audit COAs, and publish what they find. This page tracks who they are — including their own conflicts, because in this market everyone has some.

The Testing Layer

Finnrick Analytics

An independent testing service that analyzes gray-market peptides and publishes results. Two things belong on the record alongside its work: its methodology has been disputed by vendors it has failed, and it also earns revenue from services to vendors — a conflict readers should weigh, disclosed here the same way we would disclose it for anyone.

Janoshik Analytical

A Czech laboratory treated inside the community as a standard reference — many vendor COAs trace back to it. Notably, researchers compiling this tracker found no published accreditation for the lab. “Community-standard” and “accredited” are not the same claim, and the difference matters when a Janoshik report is the only document standing between a buyer and an unknown powder.

The Peptide Watch

A UK-based COA watchdog that examines certificates of analysis themselves — the document layer where the Paradigm fraud actually happened — flagging reports that do not hold up.

The Debunkers

• Dr. Andrea Love — scientist who has written for WIRED debunking peptide hype and the “research chemical” framing.
• Jonathan Jarry (McGill Office for Science and Society) — has documented that BPC-157’s research base comes almost exclusively from the same Croatian team that created it.
• Dr. Brad Stanfield — physician-creator who reviews the human evidence (and its absence) compound by compound.

The Evidence Gap They Point At

The watchdog and debunker layer converges on one documented fact pattern: for the market’s flagship compound, BPC-157, a 2025 systematic review in the American Journal of Sports Medicine screened 544 papers and found the human evidence reduced to uncontrolled pilot work — the U.S. Anti-Doping Agency’s August 2026 summary is blunt: “no human clinical trials establishing efficacy… for any diagnosis.” TB-500 has zero human trials of the fragment sold. None of that stops the sales — which is why the testing layer, conflicts and all, is part of the enforcement story.

Documented Harms, On the Record

• RAADFest, Las Vegas, July 2025: two women intubated after injections at a conference booth. Cause undetermined; Nevada’s pharmacy board fined four parties.
• KFF, October 13, 2026: users reported prolonged fatigue, anxiety and anhedonia after BPC-157 purchased from an online vendor; FDA adverse-event reports include hospitalizations.

Part of the Peptide Gray Market tracker. Sources: testing-service and watchdog publications; Am J Sports Med (2025); USADA; KFF. Compiled October 18, 2026. AllegedFraud does not endorse any testing service listed.